Sana Biotechnology, INC 8-K filings

Sana Biotechnology stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Sana Biotechnology, Inc. has raised approximately $69.0 million in net proceeds through the sale of 21,607,878 shares of common stock.

Sana Biotechnology announced first quarter 2026 financial results, highlighting a strategic collaboration with Mayo Clinic for type 1 diabetes therapy development and progress across multiple drug candidates.

Sana Biotechnology, Inc. has reclassified a Class I director to Class III to achieve a more balanced board structure.

Sana Biotechnology announced a stock purchase agreement with Mayo Clinic for up to $50 million in common stock, bolstering its operational runway into 2027.

Sana Biotechnology announced its fourth quarter and full year 2025 financial results, highlighted positive clinical progress in type 1 diabetes and blood cancers, and amended its at-the-market offering program to raise up to $150 million.

Sana Biotechnology, Inc. announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer, effective February 17, 2026.

Sana Biotechnology provides positive updates on its hypoimmune cell therapies for type 1 diabetes and in vivo CAR T cell programs, targeting significant clinical milestones in 2026.

Sana Biotechnology reported Q3 2025 financial results, prioritizing SC451 for type 1 diabetes and SG293 in vivo CAR T programs while suspending allogeneic CAR T studies.

Sana Biotechnology, Inc. announced the voluntary retirement of its Executive Vice President, General Counsel, and Corporate Secretary, Bernard J. Cassidy, and the appointment of Aaron M. Grossman as the new Executive Vice President, Chief Legal Officer.

Mary Agnes Wilderotter has resigned from Sana Biotechnology's Board of Directors, effective August 29, 2025.

Sana Biotechnology announced second quarter 2025 financial results, highlighted by positive clinical data for its type 1 diabetes program and a significant capital raise extending its cash runway into late 2026.

Sana Biotechnology, Inc. announced the pricing of a public offering of common stock and pre-funded warrants, aiming to raise approximately $70.0 million in net proceeds.

Sana Biotechnology, Inc. announced preliminary financial results including significant impairment charges, alongside positive six-month clinical trial data for its UP421 program and an at-the-market equity raise.

Sana Biotechnology, Inc. announced positive six-month clinical results from a first-in-human study of its UP421 allogeneic primary islet cell therapy, demonstrating safety, survival, and insulin production in a type 1 diabetes patient without the need for immunosuppression.

Sana Biotechnology, Inc. announced that its stockholders elected all nominated Class I directors and ratified Ernst & Young LLP as its independent auditor at the 2025 annual meeting held on June 5, 2025.

Sana Biotechnology reports positive clinical results from a type 1 diabetes study and provides business updates for the first quarter of 2025, while also announcing a new sales agreement for up to $119 million in common stock.

Sana Biotechnology reports positive preliminary clinical results from its type 1 diabetes study and provides business updates for the fourth quarter and full year 2024.

Sana Biotechnology showcased its hypoimmune platform's ability to overcome allogeneic rejection in humans, with potential applications in type 1 diabetes and autoimmune diseases.

Sana Biotechnology announced its third quarter 2024 financial results, highlighting progress in clinical trials and a strategic focus on immunologic diseases.

Sana Biotechnology's Chief Financial Officer resigned, leading to the appointment of the CEO as acting PFO and the SVP of Finance as acting PAO.

Sana Biotechnology's Executive Vice President and Chief Financial Officer, Nathan Hardy, has announced his resignation, effective October 4, 2024.

Sana Biotechnology announced its second quarter 2024 financial results, highlighting progress in clinical trials and advancements in its hypoimmune technology.

Sana Biotechnology held its 2024 annual meeting, electing three Class III directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

Sana Biotechnology announced its first quarter 2024 financial results, highlighting progress in clinical trials and a strengthened cash position.

Sana Biotechnology's Executive Vice President and President of Research and Development, Douglas Williams, Ph.D., has resigned effective April 18, 2024, for personal reasons.

Sana Biotechnology announced its fourth quarter and full year 2023 financial results, highlighting progress in clinical trials and a strengthened financial position.

Sana Biotechnology has priced an upsized public offering of common stock and pre-funded warrants, anticipating net proceeds of approximately $156.6 million.

Sana Biotechnology announces positive interim results from its ARDENT trial, along with a strong cash position of approximately $205.4 million as of January 2, 2024.